SOPHiA GENETICS
EPFL Innovation Park
Batiment D
Lausanne
CH-1015
United States
Tel: 41-21-693-90-44
Website: http://www.sophiagenetics.com/
Email: info@sophiagenetics.com
102 articles about SOPHiA GENETICS
-
SOPHiA GENETICS Announces Unilabs is using its AI Technology to Detect Homologous Recombination Deficiency (HRD)
4/17/2024
SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, announced that Unilabs, one of the largest diagnostic providers in Europe, and the only provider to offer laboratory, imaging and pathology specialties within one group, is live on the SOPHiA DDM™ Platform.
-
SOPHiA GENETICS Announces First Homologous Recombination Deficiency (HRD) Customer in Canada
3/20/2024
SOPHiA GENETICS (Nasdaq: SOPH) today announced the University of Saskatchewan (USask) as its first HRD customer in Canada.
-
SOPHiA GENETICS to Present at the Barclays 26th Annual Global Healthcare Conference
3/7/2024
SOPHiA GENETICS (Nasdaq: SOPH) today announced Chief Financial Officer and Chief Operating Officer, Ross Muken, will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13, 2024, at 2:35 p.m. EDT.
-
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2023 Results
3/5/2024
SOPHiA GENETICS reported financial results for its fourth quarter and fiscal year ended December 31, 2023.
-
SOPHiA GENETICS to Participate in Fireside Chat at the 44th Annual TD Cowen Health Care Conference
2/22/2024
SOPHiA GENETICS (Nasdaq: SOPH) today announced Co-founder and Chief Executive Officer, Dr. Jurgi Camblong, and Chief Financial Officer and Chief Operating Officer, Ross Muken, will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Wednesday, March 6, 2024, at 10:30 a.m. EDT.
-
SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024
2/20/2024
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full-year 2023 before U.S. markets open on Tuesday, March 5, 2024.
-
SOPHiA GENETICS Supports Genetic Testing in Brazil
1/25/2024
SOPHiA GENETICS announced that Bioma4me, a Brazil-based company focused on genetic sequencing to drive precision medicine to the Brazilian population, is now live on the SOPHiA DDM™ Platform.
-
SOPHiA GENETICS Highlights Near-Term Growth Strategy at 42nd Annual J.P. Morgan Healthcare Conference
1/10/2024
SOPHiA GENETICS (Nasdaq: SOPH) in a presentation at the 42nd annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 9:00 a.m. PST.
-
Exactis Innovation and SOPHiA GENETICS Announce Collaboration on Multimodal Data Analytics
1/8/2024
SOPHiA GENETICS today announced a collaboration with Exactis Innovation, based in Montreal, Quebec, who will contribute to cancer research and data-driven decision-making through SOPHiA GENETICS' multimodal real-world data offering.
-
Hôpital Saint-Louis Implements SOPHiA DDM™ Platform to Further Research of Myeloid Disorders
12/21/2023
SOPHiA GENETICS announced that Hôpital Saint-Louis, located in Paris, has implemented the SOPHiA DDM™ Platform to help advance its research of Myeloid Disorders and continue expanding the use of precision medicine for those in the area.
-
SOPHiA GENETICS Announces Expanded Suite of Liquid Biopsy Offerings
12/7/2023
SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, announced an expanded suite of solutions under SOPHiA DDM™ for Liquid Biopsy.
-
SOPHiA GENETICS Announces Expansion of Work with CHU de Nîmes
11/30/2023
SOPHiA GENETICS announced that it has expanded its work with CHU de Nîmes, a regional and university hospital located in the South of France.
-
BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™
11/7/2023
SOPHiA GENETICS announced that BioReference® Health, LLC, an OPKO Health, Inc. company and full-service laboratory that processes more than 12 million tests annually, will implement SOPHiA GENETICS' technology and add MSK-ACCESS® liquid biopsy to its test suite.
-
SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2023 Record results on growth acceleration, significant improvement in operating loss and cash burn
11/7/2023
SOPHiA GENETICS SA, a cloud-native software company and a leader in data-driven medicine, reported financial results for the third quarter ended September 30, 2023.
-
SOPHiA GENETICS to Announce Financial Results for the Third Quarter of Fiscal 2023 on November 7, 2023
10/24/2023
SOPHiA GENETICS SA, a cloud-native software company and a leader in data-driven medicine, announced it will release its financial results for the third quarter of fiscal 2023 before U.S. markets open on Tuesday, November 7, 2023.
-
Shaare Zedek Medical Center Uses SOPHiA GENETICS to Advance Research of Myeloid Disorders
9/29/2023
SOPHiA GENETICS announced that Shaare Zedek, the largest multi-disciplinary medical center in Jerusalem, is now live on the SOPHiA DDM™ Platform.
-
Laboratorio Curie Expands Relationship with SOPHiA GENETICS
9/13/2023
SOPHiA GENETICS has expanded its relationship with Laboratorio Curie.
-
SOPHiA GENETICS Announces the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) is Live on the SOPHiA DDM™ Platform
9/7/2023
SOPHiA GENETICS is helping excel the use of precision medicine to treat advanced ovarian cancer.
-
CHU Bordeaux is live on SOPHiA GENETICS
8/30/2023
SOPHiA GENETICS announced that CHU Bordeaux, a full-service hospital servicing the population of Bordeaux and the surrounding area, has completed implementation of the SOPHiA DDM™ Platform into its organization.
-
SOPHiA GENETICS Expands Relationship with Gustave Roussy
8/22/2023
SOPHiA GENETICS, a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced the expansion of its relationship with Gustave Roussy, the leading cancer center in Europe.